|
Systemic Sclerosis
Citations 51-60 of 242 total displayed.
|
Past content
(since Jan 2001):
|
- ARTICLES
A path to the future in scleroderma
- O. Distler, M. Matucci-Cerinic, U. Müller-Ladner, and J. R. Seibold
Rheumatology 2008; 47: v1.
[Extract]
[Full Text]
- MOLECULAR TARGETS FOR ANTIFIBROTIC THERAPY
Role of PDGF in fibrotic diseases and systemic sclerosis
- M. Trojanowska
Rheumatology 2008; 47: v2-v4.
[Abstract]
[Full Text]
- MOLECULAR TARGETS FOR ANTIFIBROTIC THERAPY
Pro- and anti-fibrotic effects of TGF-β in scleroderma
- R. Sgonc and G. Wick
Rheumatology 2008; 47: v5-v7.
[Abstract]
[Full Text]
- MOLECULAR TARGETS FOR ANTIFIBROTIC THERAPY
Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?
- D. Abraham
Rheumatology 2008; 47: v8-v9.
[Abstract]
[Full Text]
- MOLECULAR TARGETS FOR ANTIFIBROTIC THERAPY
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis
- J. H. W. Distler and O. Distler
Rheumatology 2008; 47: v10-v11.
[Abstract]
[Full Text]
- MOLECULAR TARGETS FOR ANTIFIBROTIC THERAPY
Criteria to select molecular targets for anti-fibrotic therapy
- J. H. W. Distler and O. Distler
Rheumatology 2008; 47: v12-v13.
[Abstract]
[Full Text]
- VASCULAR DISEASE AND ENDOTHELIN
The microvascular endothelium in scleroderma
- B. Kahaleh
Rheumatology 2008; 47: v14-v15.
[Abstract]
[Full Text]
- VASCULAR DISEASE AND ENDOTHELIN
Macrovascular disease in systemic sclerosis: the tip of an iceberg?
- J. J. F. Belch, S. McSwiggan, and C. Lau
Rheumatology 2008; 47: v16-v17.
[Abstract]
[Full Text]
- VASCULAR DISEASE AND ENDOTHELIN
Mechanisms of vascular damage in SSc—implications for vascular treatment strategies
- S. Guiducci, O. Distler, J. H. W. Distler, and M. Matucci-Cerinic
Rheumatology 2008; 47: v18-v20.
[Abstract]
[Full Text]
- VASCULAR DISEASE AND ENDOTHELIN
Biomarkers of vascular disease in scleroderma
- L. K. Hummers
Rheumatology 2008; 47: v21-v22.
[Abstract]
[Full Text]
|
|
